Type 1 diabetes

Featured

Aspect Biosystems Strikes $2.6B Bioprinted Tissue Deal with Novo Nordisk

Bioprinting collaborations are heating up in 2023. In one of the biggest moves of the bioprinting industry, Canadian startup Aspect Biosystems and Danish pharma giant Novo Nordisk (CPH: NOVO-B) struck…

Aspect Biosystems Partners With JDRF to Treat Diabetes

Canadian biotech startup Aspect Biosystems, founded and led by biomedical engineer Tamer Mohamed, has partnered with the nonprofit organization Juvenile Diabetes Research Foundation (JDRF) to develop bioengineered tissue therapeutics to…

Featured

Can Fluicell’s Bioprinted Tissue Help Treat Type 1 Diabetes?

As Swedish bioprinter manufacturer Fluicell prepares to enter the regenerative medicine market through its BioRej Advance program, it focuses on developing therapeutic products based on bioprinted transplantable microtissues targeting important…

Polbionica Could Become the Next Success Story in Organ Bioprinting

Last year, a scientific team in Warsaw, Poland, bioprinted the world’s first prototype of a bionic pancreas with a vascular system. Led by clinical transplantation expert and inventor, Michał Wszoła,…

Interview with Tamer Mohamed of Aspect Biosystems on Advancing Tissue Therapeutics

While attending The University of British Columbia (UBC), Tamer Mohamed, along with fellow graduate student Simon Beyer, began working at the Walus Laboratory on the development of a novel microfluidics-based…

3D Bioprinter Offers New Treatment for Type 1 Diabetes

Researchers at the University of Wollongong have done some impressive things. They’ve 3D printed brain tissue, and developed a 3D printing pen capable of drawing cartilage into knees. They’ve created an…

3D Printed Bioplotting May Offer Comfort to Diabetes Patients

Type 1 diabetes is a malady usually diagnosed in children and young adults, once known as juvenile diabetes. Only five percent of diabetes sufferers have this form of the disease; in…